[Edaily Reporter Hyera Lee ] ABKO CO., LTD.(129890)announced on the 26th that it will sign a new share subscription agreement with U.S.-based medical artificial intelligence (AI) company Bullseye Biodevices Inc. (Bullseye) on the 29th.

The company received the final version of the investment review report from its accounting firm today, completing its feasibility study. It plans to sign the new share subscription agreement on the 29th and finalize the investment process early next month; its stake after the acquisition will be approximately 40%.
Bullseye is a U.S. company that develops AI solutions based on medical data. Its competitiveness has been recognized by the U.S. National Science Foundation (NSF), and it receives pension fund support from the U.S. government.
The sensor currently under development is a device that, when mounted on a surgical robot, directly measures electrical, optical, and mechanical biosignals from the surgical site. It will first be applied to cancer surgeries—such as those for lung, liver, and colorectal cancers—where precise identification is critical, and the company plans to expand its scope of application to regenerative medicine, cardiovascular diseases, and degenerative diseases.
According to market research firm Grand View Research, the global surgical robotics market is projected to grow from $6.6 billion (approximately 10 trillion won) in 2025 to $18.5 billion (approximately 29 trillion won) in 2033.
Last month, at an extraordinary general meeting of shareholders, ABKO CO., LTD. laid the groundwork for new growth engines by adding new business objectives, including: △ the development and provision of AI-based medical solutions; △ intelligent medical robotics and high-precision automated control systems; and △ research and development of high-sensitivity biosensors and biosignal analysis devices based on biotechnology. The company’s strategy is to use this investment as a starting point to fully enter the medical AI and advanced healthcare sectors.
ABKO CO., LTD. stated, “We will pursue a strategy of investing in future growth industries while building on the stable revenue base secured through our existing businesses,” adding, “We will strive to ensure that our entry into the medical AI sector leads to the creation of new corporate value.”